Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1990 Nov;101(3):686–690. doi: 10.1111/j.1476-5381.1990.tb14141.x

Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs.

A Dorszewski 1, B Müller-Beckmann 1, L Kling 1, G Sponer 1
PMCID: PMC1917742  PMID: 2076485

Abstract

1. This study was performed to investigate whether cardiac positive inotropic as well as peripheral vasodilator properties of adibendan contribute to its overall haemodynamic profile in conscious dogs. 2. Haemodynamic measurements were carried out in conscious chronically instrumented dogs after administration of adibendan, sodium nitroprusside or dobutamine. 3. The cardiovascular changes induced by adibendan (0.01 and 0.03 mg kg-1) resembled those of dobutamine (1.0-4.0 micrograms kg-1 min-1): left ventricular dP/dt60 (LV dP/dt60), stroke volume (SV) and cardiac output (CO) increased to a similar extent, but mean arterial pressure (MAP) and heart rate (HR) remained unchanged. 4. In contrast to dobutamine, higher doses of adibendan (0.1-1.0 mg kg-1) decreased MAP and LVEDP. These effects were of a similar magnitude to those observed following nitroprusside administration (0.5-12.5 micrograms kg-1 min-1). In contrast to nitroprusside, adibendan still showed additional effects on LV dP/dt60 and CO. 5. From these results, it is concluded that both the peripheral vasodilator and the cardiac positive inotropic action of adibendan contribute to its overall haemodynamic profile.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bethke T., Brunkhorst D., von der Leyen H., Meyer W., Nigbur R., Scholz H. Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts. Naunyn Schmiedebergs Arch Pharmacol. 1988 May;337(5):576–582. doi: 10.1007/BF00182735. [DOI] [PubMed] [Google Scholar]
  2. Brodie B. R., Grossman W., Mann T., McLaurin L. P. Effects of sodium nitroprusside on left ventricular diastolic pressure-volume relations. J Clin Invest. 1977 Jan;59(1):59–68. doi: 10.1172/JCI108622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chatterjee K., Parmley W. W., Ganz W., Forrester J., Walinsky P., Crexells C., Swan H. J. Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction. Circulation. 1973 Dec;48(6):1183–1193. doi: 10.1161/01.cir.48.6.1183. [DOI] [PubMed] [Google Scholar]
  4. Dage R. C., Roebel L. E., Hsieh C. P., Weiner D. L., Woodward J. K. Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1.3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one). J Cardiovasc Pharmacol. 1982 May-Jun;4(3):500–508. [PubMed] [Google Scholar]
  5. Dinerman J., Mehta J. L., Nichols W. W. Systemic and coronary hemodynamic effects of prostacyclin and nitroprusside in conscious dogs. J Cardiovasc Pharmacol. 1988 Oct;12(4):492–496. doi: 10.1097/00005344-198810000-00017. [DOI] [PubMed] [Google Scholar]
  6. Dumont L., Lamoureux C., Lelorier J., Stanley P., Chartrand C. Intravenous infusion of nitroprusside: effects upon cardiovascular dynamics and regional blood flow distribution in conscious dogs. Arch Int Pharmacodyn Ther. 1983 Jan;261(1):109–121. [PubMed] [Google Scholar]
  7. Farah A. E., Alousi A. A. New cardiotonic agents: a search for digitalis substitute. Life Sci. 1978 Apr 3;22(13-15):1139–1147. doi: 10.1016/0024-3205(78)90083-8. [DOI] [PubMed] [Google Scholar]
  8. Firth B. G., Ratner A. V., Grassman E. D., Winniford M. D., Nicod P., Hillis L. D. Assessment of the inotropic and vasodilator effects of amrinone versus isoproterenol. Am J Cardiol. 1984 Dec 1;54(10):1331–1336. doi: 10.1016/s0002-9149(84)80092-2. [DOI] [PubMed] [Google Scholar]
  9. Franciosa J. A. Intravenous amrinone: an advance or a wrong step? Ann Intern Med. 1985 Mar;102(3):399–400. doi: 10.7326/0003-4819-102-3-399. [DOI] [PubMed] [Google Scholar]
  10. Freund P., Müller-Beckmann B., Strein K., Kling L., Rüegg J. C. Ca2+-sensitizing effect of BM 14.478 on skinned cardiac muscle fibres of guinea-pig papillary muscle. Eur J Pharmacol. 1987 Apr 14;136(2):243–246. doi: 10.1016/0014-2999(87)90718-7. [DOI] [PubMed] [Google Scholar]
  11. Hinds J. E., Hawthorne E. W. Comparative cardiac dynamic effects of dobutamine and isoproterenol in conscious instrumented dogs. Am J Cardiol. 1975 Dec;36(7):894–901. doi: 10.1016/0002-9149(75)90079-x. [DOI] [PubMed] [Google Scholar]
  12. Katz A. M. Cyclic adenosine monophosphate effects on the myocardium: a man who blows hot and cold with one breath. J Am Coll Cardiol. 1983 Jul;2(1):143–149. doi: 10.1016/s0735-1097(83)80387-8. [DOI] [PubMed] [Google Scholar]
  13. Liang C. S., Hood W. B., Jr Dobutamine infusion in conscious dogs with and without autonomic nervous system inhibition: effects on systemic hemodynamics, regional blood flows and cardiac metabolism. J Pharmacol Exp Ther. 1979 Dec;211(3):698–705. [PubMed] [Google Scholar]
  14. Ludmer P. L., Wright R. F., Arnold J. M., Ganz P., Braunwald E., Colucci W. S. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation. 1986 Jan;73(1):130–137. doi: 10.1161/01.cir.73.1.130. [DOI] [PubMed] [Google Scholar]
  15. Macho P., Vatner S. F. Effects of nitroglycerin and nitroprusside on large and small coronary vessels in conscious dogs. Circulation. 1981 Dec;64(6):1101–1107. doi: 10.1161/01.cir.64.6.1101. [DOI] [PubMed] [Google Scholar]
  16. Mertens A., Müller-Beckmann B., Kampe W., Hölck J. P., von der Saal W. Nonsteroidal cardiotonics. 1. 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents. J Med Chem. 1987 Aug;30(8):1279–1287. doi: 10.1021/jm00391a004. [DOI] [PubMed] [Google Scholar]
  17. Miller W. P., Ark C. R., Wiederholt P. Effect of oral milrinone on end-systolic relations in patients with severe congestive heart failure. Am J Cardiol. 1987 Oct 1;60(10):842–846. doi: 10.1016/0002-9149(87)91034-4. [DOI] [PubMed] [Google Scholar]
  18. Müller-Beckmann B., Freund P., Honerjäger P., Kling L., Rüegg J. C. In vitro investigations on a new positive inotropic and vasodilating agent (BM 14.478) that increases myocardial cyclic AMP content and myofibrillar calcium sensitivity. J Cardiovasc Pharmacol. 1988 Jan;11(1):8–16. doi: 10.1097/00005344-198801000-00002. [DOI] [PubMed] [Google Scholar]
  19. Müller-Beckmann B., Sponer G., Strein K., Bartsch W. Hemodynamic profile of BM 14.478: a new positive inotropic and vasodilating agent. J Cardiovasc Pharmacol. 1988 Jan;11(1):1–7. doi: 10.1097/00005344-198801000-00001. [DOI] [PubMed] [Google Scholar]
  20. Opie L. H. Inodilation--the way ahead in the early therapy of congestive heart failure? Cardiology. 1988;75 (Suppl 1):138–147. doi: 10.1159/000174453. [DOI] [PubMed] [Google Scholar]
  21. Pagani M., Vatner S. F., Braunwald E. Hemodynamic effects of intravenous sodium nitroprusside in the conscious dog. Circulation. 1978 Jan;57(1):144–151. doi: 10.1161/01.cir.57.1.144. [DOI] [PubMed] [Google Scholar]
  22. Pennington D. G., Vezeridis M. P., Geffin G., O'Keefe D. D., Lappas D. G., Daggett W. M. Quantitative effects of sodium nitroprusside on coronary hemodynamics and left ventricular function in dogs. Circ Res. 1979 Sep;45(3):351–359. doi: 10.1161/01.res.45.3.351. [DOI] [PubMed] [Google Scholar]
  23. Robie N. W., Nutter D. O., Moody C., McNay J. L. In vivo analysis of adrenergic receptor activity of dobutamine. Circ Res. 1974 May;34(5):663–671. doi: 10.1161/01.res.34.5.663. [DOI] [PubMed] [Google Scholar]
  24. Rowe G. G., Henderson R. H. Systemic and coronary hemodynamic effects of sodium nitroprusside. Am Heart J. 1974 Jan;87(1):83–87. doi: 10.1016/0002-8703(74)90394-9. [DOI] [PubMed] [Google Scholar]
  25. Sonnenblick E. H., Frishman W. H., LeJemtel T. H. Dobutamine: a new synthetic cardioactive sympathetic amine. N Engl J Med. 1979 Jan 4;300(1):17–22. doi: 10.1056/NEJM197901043000105. [DOI] [PubMed] [Google Scholar]
  26. Sponer G., Bartsch W., Strein K., Müller-Beckmann B., Böhm E. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol. 1987 Mar;9(3):317–327. doi: 10.1097/00005344-198703000-00009. [DOI] [PubMed] [Google Scholar]
  27. Tuttle R. R., Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975 Jan;36(1):185–196. doi: 10.1161/01.res.36.1.185. [DOI] [PubMed] [Google Scholar]
  28. Vatner S. F., McRitchie R. J., Braunwald E. Effects of dobutamine on left ventricular performance, coronary dynamics, and distribution of cardiac output in conscious dogs. J Clin Invest. 1974 May;53(5):1265–1273. doi: 10.1172/JCI107673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Veit S., Brückner J. B., Vogt K., Wagner R., Hess W. Die dosisabhängigen Wirkungen von Amrinone auf die Hämodynamik, die Myokarddurchblutung und den myokardialen Energiebedarf--Eine experimentelle Studie. Z Kardiol. 1985 Feb;74(2):76–84. [PubMed] [Google Scholar]
  30. Weisfeldt M. L., Scully H. E., Frederiksen J., Rubenstein J. J., Pohost G. M., Beierholm E., Bello A. G., Daggett W. M. Hemodynamic determinants of maximum negative dP-dt and periods of diastole. Am J Physiol. 1974 Sep;227(3):613–621. doi: 10.1152/ajplegacy.1974.227.3.613. [DOI] [PubMed] [Google Scholar]
  31. Wilmshurst P. T., Thompson D. S., Juul S. M., Jenkins B. S., Coltart D. J., Webb-Peploe M. M. Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. Br Heart J. 1984 Jul;52(1):38–48. doi: 10.1136/hrt.52.1.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. von Meel J. C. Cardiovascular effects of the positive inotropic agents pimobendan and sulmazole in vivo. Arzneimittelforschung. 1985;35(1A):284–288. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES